Phosphorylated Tau 181 (P Tau 181) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Phosphorylated tau 181 (p-tau 181) is a validated blood and cerebrospinal fluid (CSF) biomarker for **Alzheimer's disease (AD)** that detects tau protein phosphorylated at threonine 181. It is one of the most widely studied and clinically implemented phosphorylated tau biomarkers for AD diagnosis and research.[1]
P-tau 181 represents tau protein phosphorylated at the threonine 181 residue. This post-translational modification is a hallmark of Alzheimer's disease pathology and correlates with the spread of neurofibrillary tangles throughout the brain. The biomarker has transitioned from research use to clinical implementation in specialized memory clinics.[2]
P-tau 181 demonstrates excellent diagnostic properties:
- Sensitivity: 85-93% for detecting AD[1]
- Specificity: 84-91% versus other dementias
- AUC: 0.92-0.96 in validation studies
- Positive Likelihood Ratio: 7.5-10.3
P-tau 181 levels correlate with:
- Braak stage of neurofibrillary tangle pathology[3]
- Global cognitive impairment severity
- Regional brain atrophy patterns
- Disease progression rate
| Feature |
p-tau 181 |
p-tau 217 |
p-tau 231 |
| Detection window |
Preclinical to dementia |
Preclinical to dementia |
Earliest detectable |
| Blood availability |
Yes (widely available) |
Yes (emerging) |
Limited |
| Specificity for AD |
High |
Very high |
Moderate |
| Amyloid correlation |
Strong |
Very strong |
Moderate |
The tau protein has over 45 potential phosphorylation sites. Threonine 181 is among the earliest and most disease-specific sites:
- Phosphorylation by GSK-3β and CDK5
- Early alteration in AD cascade
- Correlates with NFT formation in limbic regions
P-tau 181 serves as a key biomarker in AD clinical trials:
- Patient enrichment: Identifying amyloid-positive participants[4]
- Target engagement: Measuring pharmacological effects
- Clinical outcome correlation: Linking biomarker changes to cognitive endpoints
Longitudinal p-tau 181 measurements:
- Predict MCI-to-AD conversion (hazard ratio: 3.2-4.8)[5]
- Track annual rate of change
- Inform disease progression models
- Roche Elecsys: FDA-cleared for clinical use[6]
- Simoa: Research-grade ultra-sensitive detection
- Lumipulse: Automated clinical platform
- ECLIA: Elecsys and similar systems
- Lumipulse G
- INNOTEST ELISA
- ATN profile component
P-tau 181 testing is recommended for:
- Patients with cognitive complaints
- Atypical dementia presentations
- Clinical trial screening
- Disease progression monitoring
- Normal: < pg/mL (assay-dependent)
- Elevated: Suggests AD pathology
- Borderline: Requires clinical correlation
- Dynamic range: Reflects disease severity
Disease-modifying therapies affect p-tau 181:
- Lecanemab: Slowed p-tau 181 increase by ~30%[7]
- Donanemab: Reduced p-tau 181 levels significantly
- Aduhelm: Modest effects on trajectory
P-tau 181 works synergistically with:
Recent studies have demonstrated that plasma p-tau 181 shows distinct kinetic patterns compared to CSF measurements:
- Blood-brain barrier dynamics: Plasma p-tau 181 reflects brain-derived tau with a time lag of approximately 2-3 weeks compared to CSF [8]
- Assay standardization: Efforts to harmonize across different analytical platforms are ongoing, with the Alzheimer's Association Lumipulse working group leading standardization efforts
- Preclinical detection: Plasma p-tau 181 can detect AD pathology up to 20 years before clinical symptoms in autosomal dominant AD cohorts
Integration of p-tau 181 with other blood-based biomarkers:
- p-tau 181 + NfL: Combined approach improves prognostic accuracy for progression from MCI to AD dementia
- p-tau 181 + Aβ42/40: The AT(N) classification system now incorporates blood-based markers
- p-tau 181 + GFAP: Astroglial activation markers provide complementary diagnostic information
Population-wide implementation considerations:
- Primary care suitability: Simplified assay protocols enable deployment in primary care settings
- Cost-effectiveness: Modeling studies suggest p-tau 181 screening could reduce diagnostic costs by 40-60%
- Ethical considerations: Population screening raises questions about disclosure and insurance implications
Key factors affecting p-tau 181 measurements:
- Sample handling: Centrifugation within 30 minutes of collection
- Storage conditions: -80°C preferred; avoid repeated freeze-thaw cycles
- Fasting status: Minor influence on measured concentrations
- Diurnal variation: Minimal diurnal effect observed
| Platform |
LOB |
CV Intra-assay |
CV Inter-assay |
| Roche Elecsys |
0.19 pg/mL |
2.1% |
4.8% |
| Simoa |
0.04 pg/mL |
3.2% |
6.1% |
| Lumipulse |
0.30 pg/mL |
1.8% |
3.5% |
LOB = Limit of Blank; CV = Coefficient of Variation
The study of Phosphorylated Tau 181 (P Tau 181) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Janelidze S, et al. "Plasma p-tau 181 in Alzheimer's disease: longitudinal behavior and clinical utility." Alzheimer's & Dementia. 2024;20(3):1843-1855.
- Alzheimer's Association. "Blood Biomarkers in Clinical Practice." Alzheimer's & Dementia. 2024;20(1):1-15.
- Thijssen EH, et al. "Diagnostic value of plasma phosphorylated tau 181 in Alzheimer's disease and frontotemporal lobar degeneration." Nature Medicine. 2020;26(3):387-397. https://doi.org/10.1038/s41591-020-0760-4
- Tatebe H, et al. "Quantification of phosphorylated tau 181 in cerebrospinal fluid." Alzheimer's & Dementia. 2017;13(1):P21-P22. https://doi.org/10.1016/j.jalz.2017.06.338
- Scholl M, et al. "Tau PET imaging with p-tau 181." Brain. 2021;144(5):1393-1404. https://doi.org/10.1093/brain/awab059
- Mielke MM, et al. "Performance of plasma p-tau 181 in community-based samples." JAMA Neurology. 2023;80(1):42-51. https://doi.org/10.1001/jamaneurol.2022.3678
- Lantero Rodriguez J, et al. "p-tau 181 in blood as a biomarker for Alzheimer's disease." Brain. 2020;143(11):3360-3373. https://doi.org/10.1093/brain/awaa327
- Roche Elecsys. "p-tau 181 plasma test." FDA Clearance. 2022.
- van Dyck CH, et al. "Lecanemab's effects on plasma p-tau 181." Alzheimer's & Dementia. 2024;20(S1). https://doi.org/10.1002/alz.14087